This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin 2021; 71: 7-33. doi: 10.3322/caac.21654SiegelRLMillerKDFuchsHEJemalACancer statistics, 202120217173310.3322/caac.2165433433946Open DOISearch in Google Scholar
Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009; 101: 1642-9. doi: 10.1093/jnci/djp369BroglioKRBerryDADetecting an overall survival benefit that is derived from progression-free survival20091011642910.1093/jnci/djp369413723219903805Open DOISearch in Google Scholar
Soria JC, Massard C, Le Chevalier T. Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? Ann Oncol 2010; 21: 2324-32. doi: 10.1093/annonc/mdq204SoriaJCMassardCLeChevalier TShould progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?20102123243210.1093/annonc/mdq20420497965Open DOISearch in Google Scholar
Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27: 1227-34. doi: 10.1200/JCO.2007.14.5466ReckMvon PawelJZatloukalPRamlauRGorbounovaVHirshVet alPhase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil20092712273410.1200/JCO.2007.14.546619188680Open DOISearch in Google Scholar
Saad ED, Katz A, Buyse M. Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. J Clin Oncol 2010; 28: 1958-62. doi: 10.1200/JCO.2009.25.5414SaadEDKatzABuyseMOverall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials20102819586210.1200/JCO.2009.25.541420194852Open DOISearch in Google Scholar
Sundar S, Wu J, Hillaby K, Yap J, Lilford R. A systematic review evaluating the relationship between progression free survival and post progression survival in advanced ovarian cancer. Gynecol Oncol 2012; 125: 493-9. doi: 10.1016/j.ygyno.2011.12.420SundarSWuJHillabyKYapJLilfordRA systematic review evaluating the relationship between progression free survival and post progression survival in advanced ovarian cancer2012125493910.1016/j.ygyno.2011.12.42022155676Open DOISearch in Google Scholar
Petrelli F, Barni S. Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer. Ann Oncol 2013; 24: 186-92. doi: 10.1093/annonc/mds289PetrelliFBarniSCorrelation of progression-free and post-progression survival with overall survival in advanced colorectal cancer2013241869210.1093/annonc/mds28922898038Open DOISearch in Google Scholar
Hotta K, Kiura K, Fujiwara Y, Takigawa N, Hisamoto A, Ichihara E, et al. Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review. PLoS One 2011; 6: e26646. doi: 10.1371/journal.pone.0026646HottaKKiuraKFujiwaraYTakigawaNHisamotoAIchiharaEet alRole of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review20116e2664610.1371/journal.pone.0026646321963322114662Open DOISearch in Google Scholar
Hayashi H, Okamoto I, Morita S, Taguri M, Nakagawa K. Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer. Ann Oncol 2012; 23: 1537-41. doi: 10.1093/annonc/mdr487HayashiHOkamotoIMoritaSTaguriMNakagawaKPostprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer20122315374110.1093/annonc/mdr48722039091Open DOISearch in Google Scholar
Hayashi H, Okamoto I, Taguri M, Morita S, Nakagawa K. Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy. Clin Lung Cancer 2013; 14: 261-6. doi: 10.1016/j.cllc.2012.09.006HayashiHOkamotoITaguriMMoritaSNakagawaKPostprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy201314261610.1016/j.cllc.2012.09.00623107465Open DOISearch in Google Scholar
Capewell S, Sudlow MF. Performance and prognosis in patients with lung cancer. The Edinburgh Lung Cancer Group. Thorax 1990; 45: 951-6. doi: 10.1136/thx.45.12.951CapewellSSudlowMFPerformance and prognosis in patients with lung cancer199045951610.1136/thx.45.12.9514628452177921Open DOISearch in Google Scholar
Kawaguchi T, Takada M, Kubo A, Matsumura A, Fukai S, Tamura A, et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol 2010; 5: 620-30. doi: 10.1097/JTO.0b013e3181d2dcd9KawaguchiTTakadaMKuboAMatsumuraAFukaiSTamuraAet alPerformance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC201056203010.1097/JTO.0b013e3181d2dcd920354456Open DOISearch in Google Scholar
McMillan DC. An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc 2008; 67: 257-62. doi: 10.1017/S0029665108007131McMillanDC.An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer2008672576210.1017/S002966510800713118452641Open DOISearch in Google Scholar
Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer 2004; 90: 1704-.6. doi: 10.1038/sj.bjc.6601789ForrestLMMcMillanDCMcArdleCSAngersonWJDunlopDJComparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer2004901704610.1038/sj.bjc.6601789240973715150622Open DOISearch in Google Scholar
Gioulbasanis I, Pallis A, Vlachostergios PJ, Xyrafas A, Giannousi Z, Perdikouri IE, et al. The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer. Lung Cancer 2012; 77: 383-8. doi: 10.1016/j.lungcan.2012.04.008GioulbasanisIPallisAVlachostergiosPJXyrafasAGiannousiZPerdikouriIEet alThe Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer201277383810.1016/j.lungcan.2012.04.00822551892Open DOISearch in Google Scholar
Leung EY, Scott HR, McMillan DC. Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer. J Thorac Oncol 2012; 7: 655-62. doi: 10.1097/JTO.0b013e318244ffe1LeungEYScottHRMcMillanDCClinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer201276556210.1097/JTO.0b013e318244ffe122425914Open DOISearch in Google Scholar
Umihanic S, Umihanic S, Jamakosmanovic S, Brkic S, Osmic M, Dedic S, et al. Glasgow prognostic score in patients receiving chemotherapy for non-small-cell lung cancer in stages IIIb and IV. Med Arch 2014; 68: 83-5. doi: 10.5455/ medarh.2014.68.83-85UmihanicSUmihanicSJamakosmanovicSBrkicSOsmicMDedicSet alGlasgow prognostic score in patients receiving chemotherapy for non-small-cell lung cancer in stages IIIb and IV20146883510.5455/medarh.2014.68.83-85427249324937927Open DOISearch in Google Scholar
Jiang AG, Chen HL, Lu HY. Comparison of Glasgow prognostic score and prognostic index in patients with advanced non-small cell lung cancer. J Cancer Res Clin Oncol 2015; 141: 563-8. doi: 10.1007/s00432-014-1839-4JiangAGChenHLLuHYComparison of Glasgow prognostic score and prognostic index in patients with advanced non-small cell lung cancer2015141563810.1007/s00432-014-1839-425257958Open DOISearch in Google Scholar
Simmons CP, Koinis F, Fallon MT, Fearon KC, Bowden J, Solheim TS, et al. Prognosis in advanced lung cancer – a prospective study examining key clinicopathological factors. Lung Cancer 2015; 88: 304-9. doi: 10.1016/j.lungcan.2015.03.020SimmonsCPKoinisFFallonMTFearonKCBowdenJSolheimTSet alPrognosis in advanced lung cancer – a prospective study examining key clinicopathological factors201588304910.1016/j.lungcan.2015.03.02025870155Open DOISearch in Google Scholar
Imai H, Kishikawa T, Minemura H, Yamada Y, Ibe T, Yamaguchi O, et al. Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab mono-therapy for non-small cell lung cancer. Cancer Med 2021; 10: 6971-84. doi: 10.1002/cam4.4220ImaiHKishikawaTMinemuraHYamadaYIbeTYamaguchiOet alPretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab mono-therapy for non-small cell lung cancer20211069718410.1002/cam4.4220852516534414673Open DOISearch in Google Scholar
Imai H, Kaira K, Minato K. Clinical significance of post-progression survival in lung cancer. Thorac Cancer 2017; 8:379-86. doi 10.1111/1759-7714.12463ImaiHKairaKMinatoKClinical significance of post-progression survival in lung cancer201783798610.1111/1759-7714.12463558245928627767Open DOISearch in Google Scholar
Govindan R, Bogart J, Vokes EE. Locally advanced non-small cell lung cancer: the past, present, and future. J Thorac Oncol 2008; 3: 917-28. doi: 10.1097/ JTO.0b013e318180270bGovindanRBogartJVokesEELocally advanced non-small cell lung cancer: the past, present, and future200839172810.1097/JTO.0b013e318180270b18670313Open DOISearch in Google Scholar
Sause W, Kolesar P, Taylor SI, Johnson D, Livingston R, Komaki R, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000; 117: 358-64. doi: 10.1378/chest.117.2.358SauseWKolesarPTaylorSIJohnsonDLivingstonRKomakiRet alFinal results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group20001173586410.1378/chest.117.2.35810669675Open DOISearch in Google Scholar
Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 2181-90. doi: 10.1200/JCO.2009.26.2543AuperinALe PechouxCRollandECurranWJFuruseKFournelPet alMeta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer20102821819010.1200/JCO.2009.26.254320351327Open DOISearch in Google Scholar
Vokes EE, Herndon JE, 2nd, Kelley MJ, Cicchetti MG, Ramnath N, Neill H, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007; 25: 1698-704. doi: 10.1200/JCO.2006.07.3569VokesEEHerndonJE2ndKelleyMJCicchettiMGRamnathNNeillHet alInduction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B200725169870410.1200/JCO.2006.07.356917404369Open DOISearch in Google Scholar
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 2017; 377: 1919-29. doi: 10.1056/NEJMoa1709937AntoniaSJVillegasADanielDVicenteDMurakamiSHuiRet alDurvalumab after chemoradiotherapy in stage III non-small-cell lung cancer201737719192910.1056/NEJMoa170993728885881Open DOISearch in Google Scholar
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018; 379: 2342-50. doi: 10.1056/NEJMoa1809697AntoniaSJVillegasADanielDVicenteDMurakamiSHuiRet alOverall survival with durvalumab after chemoradiotherapy in stage III NSCLC201837923425010.1056/NEJMoa180969730280658Open DOISearch in Google Scholar
Niibe Y, Hayakawa K. Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol 2010; 40: 107-11. doi: 10.1093/jjco/hyp167NiibeYHayakawaKOligometastases and oligo-recurrence: the new era of cancer therapy2010401071110.1093/jjco/hyp167281354520047860Open DOISearch in Google Scholar
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47. doi: 10.1016/j.ejca.2008.10.026EisenhauerEATherassePBogaertsJSchwartzLHSargentDFordRet alNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)2009452284710.1016/j.ejca.2008.10.02619097774Open DOISearch in Google Scholar
Johnson KR, Ringland C, Stokes BJ, Anthony DM, Freemantle N, Irs A, et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol 2006; 7: 741-6. doi: 10.1016/S1470-2045(06)70800-2JohnsonKRRinglandCStokesBJAnthonyDMFreemantleNIrsAet alResponse rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis20067741610.1016/S1470-2045(06)70800-216945769Open DOISearch in Google Scholar
Hotta K, Fujiwara Y, Matsuo K, Kiura K, Takigawa N, Tabata M, et al. Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer. J Thorac Oncol 2009; 4: 311-7. doi: 10.1097/JTO.0b013e3181989bd2HottaKFujiwaraYMatsuoKKiuraKTakigawaNTabataMet alTime to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer20094311710.1097/JTO.0b013e3181989bd219190515Open DOISearch in Google Scholar
Weir CJ, Walley RJ. Statistical evaluation of biomarkers as surrogate endpoints: a literature review. Stat Med 2006; 25: 183-203. doi: 10.1002/ sim.2319WeirCJWalleyRJStatistical evaluation of biomarkers as surrogate endpoints: a literature review20062518320310.1002/sim.231916252272Open DOISearch in Google Scholar
Fleischer F, Gaschler-Markefski B, Bluhmki E. A statistical model for the dependence between progression-free survival and overall survival. Stat Med 2009; 28: 2669-86. doi: 10.1002/sim.3637FleischerFGaschler-MarkefskiBBluhmkiEA statistical model for the dependence between progression-free survival and overall survival20092826698610.1002/sim.363719579225Open DOISearch in Google Scholar
Foster NR, Qi Y, Shi Q, Krook JE, Kugler JW, Jett JR, et al. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials. Cancer 2011; 117: 1262-71. doi: 10.1002/cncr.25526FosterNRQiYShiQKrookJEKuglerJWJettJRet alTumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials201111712627110.1002/cncr.25526302526720960500Open DOISearch in Google Scholar
Berghmans T, Pasleau F, Paesmans M, Bonduelle Y, Cadranel J, Cs Toth I, et al. Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations. Eur Respir J 2012; 39: 9-28. doi: 10.1183/09031936.00190310BerghmansTPasleauFPaesmansMBonduelleYCadranelJCsToth Iet alSurrogate markers predicting overall survival for lung cancer: ELCWP recommendations20123992810.1183/09031936.0019031021737547Open DOISearch in Google Scholar
Tsujino K, Kawaguchi T, Kubo A, Aono N, Nakao K, Koh Y, et al. Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib. J Thorac Oncol 2009; 4: 994-1001. doi: 10.1097/JTO.0b013e3181a94a2fTsujinoKKawaguchiTKuboAAonoNNakaoKKohYet alResponse rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib20094994100110.1097/JTO.0b013e3181a94a2f19633474Open DOISearch in Google Scholar
Li X, Liu S, Gu H, Wang D. Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib. J Cancer Res Clin Oncol 2012; 138: 1963-9. doi: 10.1007/s00432-012-1278-zLiXLiuSGuHWangDSurrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib20121381963910.1007/s00432-012-1278-z22763646Open DOISearch in Google Scholar
Imai H, Onozato R, Kaira K, Kawashima S, Masubuchi K, Nagashima T, et al. Course of postoperative relapse in non-small cell lung cancer is strongly associated with post-progression survival. Thorac Cancer 2021; 12: 2740-8. doi: 10.1111/1759-7714.14119ImaiHOnozatoRKairaKKawashimaSMasubuchiKNagashimaTet alCourse of postoperative relapse in non-small cell lung cancer is strongly associated with post-progression survival2021122740810.1111/1759-7714.14119852081334477313Open DOISearch in Google Scholar
Imai H, Takahashi T, Mori K, Ono A, Akamatsu H, Shukuya T, et al. Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer. Neoplasma 2014; 61: 233-40. doi: 10.4149/neo_2014_030ImaiHTakahashiTMoriKOnoAAkamatsuHShukuyaTet alIndividual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer2014612334010.4149/neo_2014_03024299320Open DOISearch in Google Scholar
Imai H, Mori K, Ono A, Akamatsu H, Taira T, Kenmotsu H, et al. Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy. Med Oncol 2014; 31: 88. doi: 10.1007/s12032-014-0088-3ImaiHMoriKOnoAAkamatsuHTairaTKenmotsuHet alIndividual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy2014318810.1007/s12032-014-0088-324961467Open DOISearch in Google Scholar
Imai H, Kaira K, Mori K, Kotake M, Mitani M, Kawashima N, et al. Post-progression survival is highly linked to overall survival in patients with non-small-cell lung cancer harboring sensitive EGFR mutations treated with first-line epidermal growth factor receptor-tyrosine kinase inhibitors. Thorac Cancer 2019; 10: 2200-8. doi: 10.1111/1759-7714.13193ImaiHKairaKMoriKKotakeMMitaniMKawashimaNet alPost-progression survival is highly linked to overall survival in patients with non-small-cell lung cancer harboring sensitive EGFR mutations treated with first-line epidermal growth factor receptor-tyrosine kinase inhibitors2019102200810.1111/1759-7714.13193688543531595714Open DOISearch in Google Scholar
Jiang T, Cheng R, Zhang G, Su C, Zhao C, Li X, et al. Characterization of liver metastasis and its effect on targeted therapy in EGFR-mutant NSCLC: a multicenter study. Clin Lung Cancer 2017; 18: 631-9. doi: 10.1016/j.cllc.2017.04.015JiangTChengRZhangGSuCZhaoCLiXet alCharacterization of liver metastasis and its effect on targeted therapy in EGFR-mutant NSCLC: a multicenter study201718631910.1016/j.cllc.2017.04.01528549835Open DOISearch in Google Scholar
Sridhar S, Paz-Ares L, Liu H, Shen K, Morehouse C, Rizvi N, et al. Prognostic significance of liver metastasis in durvalumab-treated lung cancer patients. Clin Lung Cancer 2019; 20: e601-8. doi: 10.1016/j.cllc.2019.06.020SridharSPaz-AresLLiuHShenKMorehouseCRizviNet alPrognostic significance of liver metastasis in durvalumab-treated lung cancer patients201920e601810.1016/j.cllc.2019.06.02031327642Open DOISearch in Google Scholar
Choi MG, Choi CM, Lee DH, Kim SW, Yoon S, Kim WS, et al. Different prognostic implications of hepatic metastasis according to front-line treatment in non-small cell lung cancer: a real-world retrospective study. Transl Lung Cancer Res 2021; 10: 2551-61. doi: 10.21037/tlcr-21-206ChoiMGChoiCMLeeDHKimSWYoonSKimWSet alDifferent prognostic implications of hepatic metastasis according to front-line treatment in non-small cell lung cancer: a real-world retrospective study20211025516110.21037/tlcr-21-206826433034295661Open DOISearch in Google Scholar